Vaccines for Moraxella catarrhalis.
Vaccine development for Moraxella catarrhalis is in the antigen identification stage. M. catarrhalis does not appear to synthesize secreted antigens such as exotoxins, nor does it appear to possess a carbohydrate capsule. Modified forms of these antigens are usually good vaccine components. There is some interest in whole bacterial cells and membrane fractions, but the search has largely focused on purified outer surface antigens. All of the present antigens have been selected based on the response seen in animals, although the antibody response seen in people exposed to the bacterium provides some guidance. The antibody response provides information related to the cross-strain preservation of epitopes and whether they are surface exposed. Antigens that elicit antibodies that have complement dependent bactericidal capacity, opsonophagocytic activity or interfere with one of the antigen's known functions such as adhesion or nutrient acquisition are particularly valued. In addition to examining the antibody response, some antigens have been evaluated in a murine pulmonary clearance model. Using these assays and model, several vaccine candidates have been identified. The antigens may be roughly classified by the function they serve the bacterium. One set appears to promote adhesion to host tissues and includes the hemagglutinins, ubiquitous surface protein A1 (UspA1), and possibly the CD protein. A second set is involved in nutrient acquisition. This set includes the lactoferrin binding protein A (LbpA) and lactoferrin binding protein B (LbpB), the transferrin binding protein A (TbpA) and transferrin binding protein B (TbpB), the CD and E porins, and the Catarrhalis outer membrane protein B (CopB). A third set is comprised of antigens involved in virulence and it includes lipooligosaccharide (LOS) and the ubiquitous surface protein A2 (UspA2). Antigens of unknown function, such as the 200K protein, may also be vaccine candidates. The antigens that are most suitable will be determined in clinical studies that are only beginning now.
McMichael
J C
JC
Wyeth-Lederle Vaccines, 211 Bailey Road, West Henrietta, NY 14586-9728, USA. mcmichj@war.wyeth.com
D018829:Adhesins, Bacterial / Q000276:immunology / Q000302:isolation & purification; D000368:Aged; D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D000918:Antibody Specificity; D000942:Antigens, Bacterial / Q000276:immunology* / Q000302:isolation & purification; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D001426:Bacterial Proteins / Q000276:immunology / Q000302:isolation & purification; D002352:Carrier Proteins / Q000276:immunology; D006388:Hemagglutinins / Q000276:immunology; D006801:Humans; D033862:Iron-Binding Proteins; D008070:Lipopolysaccharides / Q000276:immunology; D051379:Mice; D001936:Moraxella catarrhalis / Q000276:immunology*; D016870:Neisseriaceae Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D010033:Otitis Media / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D012141:Respiratory Tract Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D033882:Transferrin-Binding Protein B; D033863:Transferrin-Binding Proteins; D014614:Vaccines, Synthetic / Q000276:immunology*; D014774:Virulence
D018829:Adhesins, Bacterial; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D001426:Bacterial Proteins; C090131:CD protein, Branhamella; D002352:Carrier Proteins; C093197:CopB protein, Moraxella; D006388:Hemagglutinins; D033862:Iron-Binding Proteins; D008070:Lipopolysaccharides; D033882:Transferrin-Binding Protein B; D033863:Transferrin-Binding Proteins; C089675:UspA protein, Moraxella catarrhalis; D014614:Vaccines, Synthetic; C027768:lactoferrin binding proteins, bacterial